Medical News

RSS

Liberals agitated by compromise, but appear to back health reform

Politico reports that liberals are accruing a long list of reasons to be upset about the health reform negotiations: "A single-payer plan, a public option, a state 'opt-out' of the public option, a trigger and a Medicare buy-in — all ideas pushed by Democrats and blessed by [President] Obama at various times but now gone from the bill."

16 Dec 2009

Ivy Foundation awards nearly $10M for new patient-focused brain cancer research projects

Today, the Ben and Catherine Ivy Foundation (Ivy Foundation), announced that it is funding roughly $10 million for four new patient-focused research projects. As with all Ivy Foundation awards, these projects focus on improving the survival and quality of life for people with brain tumors but also specifically address new strategies to improve treatment development.

16 Dec 2009

Poll: Public cooling to health reform as debate drags on

"As the Senate struggles to meet a self-imposed, year-end deadline to complete work on legislation to overhaul the nation's health-care system, a new Washington Post-ABC News poll finds the public generally fearful that a revamped system would bring higher costs while worsening the quality of their care," The Washington Post reports. "A bare majority of Americans still believe government action is needed to control runaway health-care costs and expand coverage to the roughly 46 million people without insurance."

16 Dec 2009

ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA

ChemoCentryx, Inc. today announced that it has begun enrolling patients in a Phase 2 clinical trial of CCX354, an orally-bioavailable, novel, small molecule drug designed to specifically target the CCR1 chemokine receptor for the treatment of rheumatoid arthritis (RA).

16 Dec 2009

Tea Party protestors rally against health bills at Capitol protest

The most vocal opponents of the health bills, Tea Party protestors, took to the Capitol yesterday.

16 Dec 2009

Immigrants lose lawsuit against hospital in Atlanta

"Efforts to force the public hospital [in Atlanta, Ga.] to continue providing free dialysis treatment to a group of immigrants, most of them illegal, suffered a setback on Tuesday when a judge dismissed a lawsuit challenging the recent closing of the hospital's outpatient renal clinic," The New York Times reports.

16 Dec 2009

Makefield Therapeutics to patent applications covering its Hybrid Nanoparticle drug delivery platform

Makefield Therapeutics, Inc., an emerging therapeutics company, today announced that it has obtained an exclusive license from Albert Einstein College of Medicine of Yeshiva University to patent applications covering Makefield's biodegradable Hybrid Nanoparticles™, a versatile new drug delivery platform.

16 Dec 2009

EMD Serono, Brigham and Women's Hospital collaborate in MS research

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced a strategic collaboration with Brigham and Women's Hospital in Boston, to advance basic and clinical research in multiple sclerosis (MS), with the goal of generating new and innovative discoveries that advance treatment for people living with this condition. The multi-faceted agreement will run for up to 5 years, with the potential to renew the alliance thereafter. Both parties decided not to disclose financial details.

16 Dec 2009

Advanced Life Sciences Holdings' Restanza promising against tularemia

Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), today announced positive top-line results from a pivotal, non-human primate study of its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin) against an inhaled lethal dose of tularemia. A 14-day course of Restanza achieved a 100% survival rate at the doses tested. All of the ten animals in the study that received 16 mg/kg once-a-day of Restanza (approximate to a human dose of 300 mg) within 24 hours after exposure to a lethal dose of inhaled tularemia survived while only one of the ten animals that received placebo survived.

16 Dec 2009

Keryx Biopharmaceuticals initiates Phase 3 registration clinical trial for perifosine

Æterna Zentaris Inc., a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the initiation, by its partner Keryx Biopharmaceuticals Inc., of a Phase 3 registration clinical trial for perifosine (KRX-0401), the Company's PI3K/Akt pathway inhibitor, in relapsed/refractory multiple myeloma patients.

16 Dec 2009

Amendment to allow drug importation fails in Senate

A bipartisan plan to allow Americans to buy cheaper prescription drugs from suppliers in other countries, such as Canada, failed Tuesday in the Senate. The Wall Street Journal reports the two top supporters of the plan, Sens. Byron Dorgan, D-N.D., and John McCain, R-Ariz., said shopping overseas via the Internet and mail-order companies could save consumers up to $80 billion over a decade if their amendment were added to the health overhaul legislation.

16 Dec 2009

Positive results from Onset Therapeutics' BenzEFoam Emollient Foam skin moisturization study

Onset Therapeutics, a specialty pharmaceutical company focused in dermatology, today announced positive results from a skin moisturization study that compared the Company’s recently launched BenzEFoam™ (benzoyl peroxide 5.3%) Emollient Foam to a market leading combination gel containing clindamycin 1% - benzoyl peroxide 5%. BenzEFoam™ Emollient Foam is indicated for the topical treatment of mild to moderate acne vulgaris and is the first prescription foam formulation containing benzoyl peroxide as the active ingredient.

16 Dec 2009

Xencor's initiation of novel monoclonal antibody human clinical trial triggers milestone payment from Pfizer

Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, announced today that the Company received a milestone payment from Pfizer Inc. The amount of the payment was not disclosed. The payment was triggered by the initiation of human clinical trials of a novel monoclonal antibody therapeutic that was optimized using Xencor technologies under a March 2009 technology license agreement.

16 Dec 2009

MAQUET Cardiovascular signs single source provider contract with Novation for its VASOVIEW EVH System

MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced that it has signed a three-year single source provider contract with Novation, the industry's leading supply contracting company, for MAQUET's market-leading VASOVIEW Endoscopic Vessel Harvesting (EVH) Systems.

16 Dec 2009

Encouraging early clinical results for treatment of KC with Avedro's Keraflex KXL technology

During the 5th International Congress of Corneal Cross Linking for Keratoconus in Leipzig, Germany on December 5th, Avedro presented encouraging early clinical results for treating keratoconus, a progressive disease of the cornea of the eye. The procedure, known as Keraflex® KXL, is non-incisional and reshapes the cornea without removing any tissue.

16 Dec 2009

Cost-effective alternative to original Medicare or Medicare supplement plan for Syracuse-area residents

At a time when many people with Medicare in Syracuse are increasingly concerned about finding affordable health insurance, they now have a new Medicare Advantage option for 2010.

16 Dec 2009

Biostar Pharmaceuticals to acquire a Xi'an-based medical equipment and nutrients manufacturer for $1.1M

Biostar Pharmaceuticals, Inc., a Xianyang-based developer, manufacturer and supplier of pharmaceutical products and medical nutrients addressing a variety of diseases and conditions, today announced it has signed a letter of intent ("LOI') with a Xi'an-based medical equipment and nutrients manufacturer ("Acquiree") to acquire 100% of the Acquiree for $1.1 million in cash.

16 Dec 2009

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that data presented at a major medical meeting showed that its lead compound GLYX-13 demonstrated robust antidepressant-like and anxiolytic-like activity with no signs of the CNS-related side effects seen with other drugs targeting the NMDA receptor.

16 Dec 2009

Reprints Desk signs distribution deals with seven STM journal publishers

Derycz Scientific, Inc., a company that is pioneering a fresh way of facilitating the flow of information from content publishers to enterprise customers and their constituents, today announced that wholly-owned subsidiary Reprints Desk, Inc. has signed distribution deals with seven additional scientific, technical and medical (STM) journal publishers, expanding the pay-per-view content available to Reprints Desk customers and enhancing the speed of delivery.

16 Dec 2009

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that it has initiated a Phase I clinical trial of its lead compound GLYX-13 and has successfully dosed the first subjects in the study.

16 Dec 2009

Medical News

Liberals agitated by compromise, but appear to back health reform

Ivy Foundation awards nearly $10M for new patient-focused brain cancer research projects

Poll: Public cooling to health reform as debate drags on

ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA

Tea Party protestors rally against health bills at Capitol protest

Immigrants lose lawsuit against hospital in Atlanta

Makefield Therapeutics to patent applications covering its Hybrid Nanoparticle drug delivery platform

EMD Serono, Brigham and Women's Hospital collaborate in MS research

Advanced Life Sciences Holdings' Restanza promising against tularemia

Keryx Biopharmaceuticals initiates Phase 3 registration clinical trial for perifosine

Amendment to allow drug importation fails in Senate

Positive results from Onset Therapeutics' BenzEFoam Emollient Foam skin moisturization study

Xencor's initiation of novel monoclonal antibody human clinical trial triggers milestone payment from Pfizer

MAQUET Cardiovascular signs single source provider contract with Novation for its VASOVIEW EVH System

Encouraging early clinical results for treatment of KC with Avedro's Keraflex KXL technology

Cost-effective alternative to original Medicare or Medicare supplement plan for Syracuse-area residents

Biostar Pharmaceuticals to acquire a Xi'an-based medical equipment and nutrients manufacturer for $1.1M

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Reprints Desk signs distribution deals with seven STM journal publishers

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Latest News